battle of glp 1 delivery technologies New Drug System Could Reduce GLP-1 Shortage and Make It More Efficient Battle of GLP-1 delivery technologies
Description
Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, et al
For the efficacy estimand, the LSM change in HbA1c from baseline at week 52 as the primary endpoint was 2.24%, 2.43%, and 2.58% with tirzepatide 5, 10, and 15 mg, respectively, versus 1.44% with insulin glargine
Phentermine/topiramate for the treatment of adolescent obesity
Contributor Information Gavin N
Over time, that might mean a new normal of smarter choices
Nausea, diarrhea, vomiting, and constipation commonly occur within the first month of starting.[ref][ref] Note that for many people, gastrointestinal side effects seem to be dose-related
